Paper Contents
Abstract
Stem cells are undifferentiated cells with the unique ability to self-renew and differentiate into specialized cell types, offering immense therapeutic potential in regenerative medicine and oncology. Their capacity to repair or replace damaged tissues has led to advances in treating hematological malignancies, neurodegenerative disorders, and various cancers. Stem cellbased therapies, including hematopoietic and mesenchymal stem cells, are being extensively studied for their role in modulating tumor microenvironments, enhancing immune responses, and serving as vehicles for targeted drug and gene delivery. Despite these promising developments, challenges such as immune rejection, tumorigenic risk, and ethical considerations remain barriers to clinical translation. Recent advancements in induced pluripotent stem cell (iPSC) technology and gene-editing tools like CRISPRCas9 have further expanded the horizon for personalized and precision medicine. Continued research into stem cell biology and safety profiling is essential for realizing their full potential in therapeutic applications and disease modeling.
Copyright
Copyright © 2025 Miss. Harshada Sharad Shinde, Mrs. Pranjal D. Lohakane, Dr. Megha T. Salve.. This is an open access article distributed under the Creative Commons Attribution License.
